Your browser doesn't support javascript.
loading
Defective lipid signalling caused by mutations in PIK3C2B underlies focal epilepsy.
Gozzelino, Luca; Kochlamazashvili, Gaga; Baldassari, Sara; Mackintosh, Albert Ian; Licchetta, Laura; Iovino, Emanuela; Liu, Yu Chi; Bennett, Caitlin A; Bennett, Mark F; Damiano, John A; Zsurka, Gábor; Marconi, Caterina; Giangregorio, Tania; Magini, Pamela; Kuijpers, Marijn; Maritzen, Tanja; Norata, Giuseppe Danilo; Baulac, Stéphanie; Canafoglia, Laura; Seri, Marco; Tinuper, Paolo; Scheffer, Ingrid E; Bahlo, Melanie; Berkovic, Samuel F; Hildebrand, Michael S; Kunz, Wolfram S; Giordano, Lucio; Bisulli, Francesca; Martini, Miriam; Haucke, Volker; Hirsch, Emilio; Pippucci, Tommaso.
Afiliación
  • Gozzelino L; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
  • Kochlamazashvili G; Department of Molecular Pharmacology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Strasse 10, 13125 Berlin, Germany.
  • Baldassari S; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Mackintosh AI; Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, F-75013 Paris, France.
  • Licchetta L; Department of Molecular Pharmacology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Strasse 10, 13125 Berlin, Germany.
  • Iovino E; IRCCS Istituto delle Scienze Neurologiche di Bologna, Epilepsy Center (Reference Center for Rare and Complex Epilepsies-EpiCARE), Bologna, Italy.
  • Liu YC; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Bennett CA; Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
  • Bennett MF; Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
  • Damiano JA; Department of Medical Biology, University of Melbourne, Melbourne, VictoriaAustralia.
  • Zsurka G; Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
  • Marconi C; Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
  • Giangregorio T; Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
  • Magini P; Department of Medical Biology, University of Melbourne, Melbourne, VictoriaAustralia.
  • Kuijpers M; Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
  • Maritzen T; Department of Experimental Epileptology and Cognition Research and Department of Epileptology, University Bonn Medical Center, Venusberg Campus 1, D-53105 Bonn, Germany.
  • Norata GD; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Baulac S; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Canafoglia L; U.O. Genetica Medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Seri M; Department of Molecular Pharmacology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Strasse 10, 13125 Berlin, Germany.
  • Tinuper P; Department of Molecular Pharmacology and Cell Biology, Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP), Robert-Roessle-Strasse 10, 13125 Berlin, Germany.
  • Scheffer IE; Department of Nanophysiology, Technische Universität Kaiserslautern, 67663 Kaiserslautern, Germany.
  • Bahlo M; Department of Excellence in Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan and Center for the Study of Atherosclerosis, SISA Bassini Hospital Cinisello B, Italy.
  • Berkovic SF; Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, F-75013 Paris, France.
  • Hildebrand MS; Unit of Integrated Diagnostics for Epilepsy, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Kunz WS; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Giordano L; U.O. Genetica Medica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Bisulli F; IRCCS Istituto delle Scienze Neurologiche di Bologna, Epilepsy Center (Reference Center for Rare and Complex Epilepsies-EpiCARE), Bologna, Italy.
  • Martini M; Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
  • Haucke V; Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia.
  • Hirsch E; Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Melbourne, Victoria, Australia.
  • Pippucci T; Florey Institute for Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria, Australia.
Brain ; 145(7): 2313-2331, 2022 07 29.
Article en En | MEDLINE | ID: mdl-35786744
Epilepsy is one of the most frequent neurological diseases, with focal epilepsy accounting for the largest number of cases. The genetic alterations involved in focal epilepsy are far from being fully elucidated. Here, we show that defective lipid signalling caused by heterozygous ultra-rare variants in PIK3C2B, encoding for the class II phosphatidylinositol 3-kinase PI3K-C2ß, underlie focal epilepsy in humans. We demonstrate that patients' variants act as loss-of-function alleles, leading to impaired synthesis of the rare signalling lipid phosphatidylinositol 3,4-bisphosphate, resulting in mTORC1 hyperactivation. In vivo, mutant Pik3c2b alleles caused dose-dependent neuronal hyperexcitability and increased seizure susceptibility, indicating haploinsufficiency as a key driver of disease. Moreover, acute mTORC1 inhibition in mutant mice prevented experimentally induced seizures, providing a potential therapeutic option for a selective group of patients with focal epilepsy. Our findings reveal an unexpected role for class II PI3K-mediated lipid signalling in regulating mTORC1-dependent neuronal excitability in mice and humans.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epilepsias Parciales / Fosfatidilinositol 3-Quinasas Clase II Límite: Animals / Humans Idioma: En Revista: Brain Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Epilepsias Parciales / Fosfatidilinositol 3-Quinasas Clase II Límite: Animals / Humans Idioma: En Revista: Brain Año: 2022 Tipo del documento: Article País de afiliación: Italia
...